Kidney Cancer (Renal Cell Cancer) Pipeline Review, H1 2013


#166298

492pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Kidney Cancer (Renal Cell Cancer) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer (Renal Cell Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer (Renal Cell Cancer). 

Kidney Cancer (Renal Cell Cancer) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Kidney Cancer (Renal Cell Cancer).
  • A review of the Kidney Cancer (Renal Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Kidney Cancer (Renal Cell Cancer) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 7
Kidney Cancer (Renal Cell Cancer) Overview 8
Therapeutics Development 9
Kidney Cancer (Renal Cell Cancer) Therapeutics under Development by Companies 11
Kidney Cancer (Renal Cell Cancer) Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 21
Mid Clinical Stage Products 22
Early Clinical Stage Products 23
Discovery and Pre-Clinical Stage Products 24
Kidney Cancer (Renal Cell Cancer) Therapeutics Products under Development by Companies 25
Kidney Cancer (Renal Cell Cancer) Therapeutics Products under Investigation by Universities/Institutes 34
Companies Involved in Kidney Cancer (Renal Cell Cancer) Therapeutics Development 37
Kidney Cancer (Renal Cell Cancer) Therapeutics Assessment 115
Drug Profiles 122
Kidney Cancer (Renal Cell Cancer) Therapeutics Drug Profile Updates 366
Kidney Cancer (Renal Cell Cancer) Therapeutics Discontinued Products 454
Kidney Cancer (Renal Cell Cancer) Therapeutics - Dormant Products 457
Kidney Cancer (Renal Cell Cancer) Product Development Milestones 466

Appendix 476

Number of Products Under Development for Kidney Cancer (Renal Cell Cancer), H1 2013 24
Products under Development for Kidney Cancer (Renal Cell Cancer) Comparative Analysis, H1 2013 25
Number of Products under Development by Companies, H1 2013 27
Number of Products under Development by Companies, H1 2013 (Contd..1) 28
Number of Products under Development by Companies, H1 2013 (Contd..2) 29
Number of Products under Development by Companies, H1 2013 (Contd..3) 30
Number of Products under Development by Companies, H1 2013 (Contd..4) 31
Number of Products under Development by Companies, H1 2013 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H1 2013 34
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 35
Comparative Analysis by Late Stage Development, H1 2013 36
Comparative Analysis by Mid Clinical Stage Development, H1 2013 37
Comparative Analysis by Early Clinical Stage Development, H1 2013 38
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 39
Products under Development by Companies, H1 2013 40
Products under Development by Companies, H1 2013 (Contd..1) 41
Products under Development by Companies, H1 2013 (Contd..2) 42
Products under Development by Companies, H1 2013 (Contd..3) 43
Products under Development by Companies, H1 2013 (Contd..4) 44
Products under Development by Companies, H1 2013 (Contd..5) 45
Products under Development by Companies, H1 2013 (Contd..6) 46
Products under Development by Companies, H1 2013 (Contd..7) 47
Products under Development by Companies, H1 2013 (Contd..8) 48
Products under Investigation by Universities/Institutes, H1 2013 49
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 50
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 51
Bristol-Myers Squibb Company, H1 2013 52
Boehringer Ingelheim GmbH, H1 2013 53
Kyowa Hakko Kirin Co., Ltd., H1 2013 54
Amgen Inc., H1 2013 55
AstraZeneca PLC, H1 2013 56
Eli Lilly and Company, H1 2013 57
GlaxoSmithKline plc, H1 2013 58
Genentech, Inc., H1 2013 59
Antigenics, Inc., H1 2013 60
Inovio Biomedical Corporation, H1 2013 61
Bavarian Nordic A/S, H1 2013 62
Amorfix Life Sciences Ltd., H1 2013 63
Celltrion, Inc., H1 2013 64
Novartis AG, H1 2013 65
Astellas Pharma Inc., H1 2013 66
Ono Pharmaceutical Co., Ltd., H1 2013 67
Pfizer Inc., H1 2013 68
Taiho Pharmaceutical Co., Ltd., H1 2013 69
Exelixis, Inc., H1 2013 70
Alfacell Corporation, H1 2013 71
Onyx Pharmaceuticals, Inc., H1 2013 72
Bayer AG, H1 2013 73
Hemispherx Biopharma, Inc., H1 2013 74
Celldex Therapeutics, Inc., H1 2013 75
Active Biotech AB, H1 2013 76
AEterna Zentaris Inc., H1 2013 77
Lorus Therapeutics Inc, H1 2013 78
Lpath, Inc., H1 2013 79
Bionomics Limited, H1 2013 80
Northwest Biotherapeutics, Inc., H1 2013 81
Cleveland BioLabs, Inc., H1 2013 82
Flamel Technologies S.A., H1 2013 83
Dendreon Corporation, H1 2013 84
Green Cross Corporation, H1 2013 85
Innocell Corporation, H1 2013 87
Threshold Pharmaceuticals, Inc., H1 2013 88
Rexahn Pharmaceuticals, Inc., H1 2013 89
Spectrum Pharmaceuticals, Inc., H1 2013 90
Debiopharm Group, H1 2013 91
Colby Pharmaceutical Company, H1 2013 92
Wilex AG, H1 2013 93
Chipscreen Biosciences Ltd, H1 2013 94
Biotecnol SA, H1 2013 95
Cadila Pharmaceuticals Ltd., H1 2013 97
immatics biotechnologies GmbH, H1 2013 98
Curacyte AG, H1 2013 99
Cytheris SA, H1 2013 100
Alethia Biotherapeutics Inc., H1 2013 102
GenSpera, Inc., H1 2013 103
Cerulean Pharma, Inc., H1 2013 104
MacroGenics, Inc., H1 2013 105
Neotropix, Inc., H1 2013 106
Innate Therapeutics Limited, H1 2013 107
Deciphera Pharmaceuticals, LLC, H1 2013 108
MSM Protein Technologies, Inc., H1 2013 109
Vascular Biogenics Ltd., H1 2013 110
Jennerex Biotherapeutics, Inc., H1 2013 111
Advenchen Laboratories, LLC, H1 2013 112
Pharminox Limited, H1 2013 113
Esperance Pharmaceuticals, Inc., H1 2013 114
Welichem Biotech Inc., H1 2013 115
Tigris Pharmaceuticals, Inc., H1 2013 117
TRACON Pharmaceuticals, Inc., H1 2013 118
KAHR medical Ltd., H1 2013 119
Advanced Cancer Therapeutics, H1 2013 120
Anaphore, Inc., H1 2013 121
SAIC-Frederick, Inc., H1 2013 122
RECEPTA Biopharma S.A., H1 2013 123
n.v. BRUCELLS s.a., H1 2013 124
Medical Enzymes AG, H1 2013 125
BiOrion Technologies B.V., H1 2013 127
IkerChem S.L., H1 2013 128
Ampio Pharmaceuticals, Inc., H1 2013 129
Assessment by Monotherapy Products, H1 2013 130
Assessment by Combination Products, H1 2013 131
Assessment by Stage and Route of Administration, H1 2013 133
Assessment by Stage and Molecule Type, H1 2013 136
Kidney Cancer (Renal Cell Cancer) Therapeutics Drug Profile Updates 381
Kidney Cancer (Renal Cell Cancer) Therapeutics Discontinued Products 469
Kidney Cancer (Renal Cell Cancer) Therapeutics Discontinued Products (Contd..1) 470
Kidney Cancer (Renal Cell Cancer) Therapeutics Discontinued Products (Contd..2) 471
Kidney Cancer (Renal Cell Cancer) Therapeutics Dormant Products 472
Kidney Cancer (Renal Cell Cancer) Therapeutics Dormant Products (Contd..1) 473
Kidney Cancer (Renal Cell Cancer) Therapeutics Dormant Products (Contd..2) 474
Kidney Cancer (Renal Cell Cancer) Therapeutics Dormant Products (Contd..3) 475
Kidney Cancer (Renal Cell Cancer) Therapeutics Dormant Products (Contd..4) 476
Kidney Cancer (Renal Cell Cancer) Therapeutics Dormant Products (Contd..5) 477
Kidney Cancer (Renal Cell Cancer) Therapeutics Dormant Products (Contd..6) 478
Kidney Cancer (Renal Cell Cancer) Therapeutics Dormant Products (Contd..7) 479
Kidney Cancer (Renal Cell Cancer) Therapeutics Dormant Products (Contd..8) 480
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2013 24
Products under Development for Kidney Cancer (Renal Cell Cancer) Comparative Analysis, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Investigation by Universities/Institutes, H1 2013 33
Late Stage Products, H1 2013 36
Mid Clinical Stage Products, H1 2013 37
Early Clinical Stage Products, H1 2013 38
Discovery and Pre-Clinical Stage Products, H1 2013 39
Assessment by Monotherapy Products, H1 2013 130
Assessment by Combination Products, H1 2013 131
Assessment by Route of Administration, H1 2013 132
Assessment by Stage and Route of Administration, H1 2013 133
Assessment by Molecule Type, H1 2013 134
Assessment by Stage and Molecule Type, H1 2013 135